333586
Population prevalence of problem gambling in Massachusetts: Results of a comprehensive baseline survey and implications for state mental & behavioral health systems
Methods. The survey employed an address-based sampling strategy and multi-mode interviews. Descriptive statistics were run using SAS-callable SUDAAN.
Results. We calculated a problem gambling prevalence rate of 1.8% (CI 1.4%-2.2%). Co-occurring mood and substance use disorders of respondents with gambling problems included depression (30.7%, CI 21.3%-42.0%), tobacco use (31.7%, CI 22.5%-42.6%), illegal drug use (23.6%, CI 14.8%-35.4%) and binge drinking (53.6%, CI 42.3%-64.6%). We will also present characteristics of low-, moderate-, and high-risk gamblers; awareness of problem gambling prevention programs; and use of treatment services.
Conclusions. Results will be used to make recommendations to improve problem gambling service provision in Massachusetts.
Learning Areas:
EpidemiologyOther professions or practice related to public health
Public health or related research
Social and behavioral sciences
Learning Objectives:
Identify problem gambling as a public health issue.
Describe the prevalence of problem gambling in Massachusetts and mental health disorders (e.g., depression, anxiety, mood disorders) common among problem gamblers.
Identify gaps between population prevalence of problem gambling and awareness of prevention program and treatment services for problem gamblers.
Keyword(s): Mental Health, Mental Health Treatment &Care
Qualified on the content I am responsible for because: I have been the principal or co-principal investigator of multiple studies focused on gambling, problem gambling, and associated risk factors. Among my scientific interests has been improving understanding of risk factors related to problem gambling and transitions into and out of problem gambling status.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.